Chapter 4.3 Modulation of anxiety behaviors by 5-HT-interacting drugs

Handbook of Behavioral Neuroscience

Volumn 17, Issue , 2008, Pages 241-268

  Guimarães, Francisco Silveira ^a   Carobrez, Antonio Pádua ^b   Graeff, Frederico Guilherme ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

amygdala; antidepressants; anxiety; anxiolytics; hippocampus; panic; periaqueductal gray; serotonin

Indexed keywords

EID: 67649696958     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-7339(07)00012-4     Document Type: Review

References (226)

1. Adamec R., Burton P., Blundell J., Murphy D.L., and Holmes A. Vulnerability to mild predator stress in serotonin transporter knockout mice. Behav. Brain Res. 170 (2006) 126-140
2. Amital D., Fostick L., Sasson Y., Kindler S., Amital H., and Zohar J. Anxiogenic effects of sumatriptan in panic patients: a double-blind, placebo-controlled study. Eur. Neuropsychopharmacol. 15 (2005) 279-282
3. Andrade T.G.C.S., Macedo C.E.A., Zangrossi Jr. H., and Graeff F.G. Role of the median raphe nucleus in the modulation of two types of fear/anxiety responses in rats submitted to the elevated T-maze. J. Psychopharmacol. 14 Suppl. (2000) A38
4. Andrade T.G.C.S., Macedo C.E.A., Zangrossi Jr. H., and Graeff F.G. Anxiolytic-like effects of median raphe nucleus lesion in the elevated T-maze. Behav. Brain Res. 153 (2004) 55-60
5. Ansorge M.S., Zhou M., Lira A., Hen R., and Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306 (2004) 879-881
6. Arango V., Underwood M.D., Boldrini M., Tamir H., Kassir S.A., Hsiung S., Chen J.J., and Mann J.J. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 25 (2001) 892-903
7. Argyropoulos S.V., Hood S.D., Adrover M., Bell C.J., Rich A.S., Nash J.R., Rich N.C., Witchel H.J., and Nutt D.J. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol. Psychiatry 56 (2004) 503-509
8. Audi E.A., and Graeff F.G. Benzodiazepine receptors in the periaqueductal gray mediate anti-aversive drug action. Eur. J. Pharmacol. 103 (1984) 279-285
9. Azmitia E.C., and Segal M. An autodiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 179 (1978) 641-688
10. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R.T., den Boer J.A., Fineberg N.A., Knapp M., Scott J., and Wittchen H.U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 19 (2005) 567-596
11. Barnes N., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
12. Barr C.S., Newman T.K., Shannon C., Parker C., Dvoskin R.L., Becker M.L., Schwandt M., Champoux M., Lesch K.P., Goldman D., Suomi S.J., and Higley J.D. Rearing condition and rh5-HTTLPR interact to influence limbic-hypothalamic-pituitary-adrenal axis response to stress in infant macaques. Biol. Psychiatry 55 (2004) 733-738
13. Bastani B., Nash J.F., and Meltzer H.Y. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch. Gen. Psychiatry 47 (1990) 833-839
14. 1A receptors antagonist WAY 100635 on periaqueductal grey-induced defence behaviour. J. Psychopharmacol. 11 (1997) 35-40
15. 1 receptor agonists administered into the periaqueductal gray. Psychopharmacology 108 (1992) 110-114
16. Beijamini V., and Andreatini R. Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze. Pharmacol. Res. 48 (2003) 199-207
17. Bell C., Forshall S., Adrover M., Nash J., Hood S., Argyropoulos S., Rich A., and Nutt D.J. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J. Psychopharmacol. 16 (2002) 5-14
18. Belzung C. Rodent models of anxiety-like behaviors: are they predictive for compounds acting via non-benzodiazepine mechanisms?. Curr. Opin. Investig. Drugs 2 (2001) 1108-1111
19. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., Mossner R., Westphal H., and Lesch K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53 (1998) 649-655
20. Bennett A.J., Lesch K.-P., Heils A., Long J.C., Lorenz J.G., Shoaf S.E., Champoux M., Suomi S.J., Linnoila M.V., and Higley J.D. Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol. Psychiatry 7 (2002) 118-122
21. 2-induced anxiety in healthy volunteers with the serotonin antagonist metergoline. Am. J. Psychiatry 156 (1999) 1635-1637
22. Berney A., Sookman D., Leyton M., Young S.N., and Benkelfat C. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol. Psychiatry 59 (2006) 853-857
23. Blanchard D.C., Griebel G., and Blanchard R.J. The mouse defense test battery: pharmacological and behavioral assay for anxiety and panic. Eur. J. Pharmacol. 463 (2003) 97-116
24. Blanchard D.C., Hynd A.L., Minke K.A., Minemoto T., and Blanchard R.J. Human defensive behaviors to threat scenarios show parallels to fear- and anxiety-related defense patterns on non-human mammals. Neurosci. Biobehav. Rev. 25 (2001) 761-770
25. Blier P., and Abbott F.V. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psychiatry Neurosci. 26 (2001) 37-43
26. 1A agonists in the treatment of depression?. Biol. Psychiatry 53 (2003) 193-203
27. Boess F.G., Beroukhim R., and Martin I.L. Ultrastructure of the 5-hydroxytryptamine 3 receptor. J. Neurochem. 64 (1995) 1401-1405
28. Bonne O., Bain E., Neumeister A., Nugent A.C., Vythilingam M., Carson R.E., Luckenbaugh D.A., Eckelman W., Herscovitch P., Drevets W.C., and Charney D.S. No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. Am. J. Psychiatry 162 (2005) 383-385
29. Bourin M., and Hascoet M. The mouse light/dark box test. Eur. J. Pharmacol. 463 (2003) 55-65
30. Brandão M.L., de Aguiar J.C., and Graeff F.G. GABA mediation of the anti-aversive action of minor tranquilizers. Pharmacol. Biochem. Behav. 16 (1982) 397-402
31. Broocks A., Bandelow B., George A., Jestrabeck C., Opitz M., Bartmann U., Gleiter C.H., Meineke I., Roed I.S., Ruther E., and Hajak G. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int. Clin. Psychopharmacol. 15 (2000) 153-161
32. Canteras N.S. The medial hypothalamic defensive system: hodological organization and functional implications. Pharmacol. Biochem. Behav. 71 (2002) 481-491
33. 1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol. Biochem. Behav. 58 (1997) 593-603
34. Carey P.D., Warwick J., Niehaus D.J., van der Linden G., van Heerden B.B., Harvey B.H., Seedat S., and Stein D.J. Single photon emission computed tomography (SPECT). B.M.C. Psychiatry 4 (2004) 30
35. Carobrez A.P., and Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci. Biobehav. Rev. 29 (2005) 1193-1205
36. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., and Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
37. Ceulemans D.L.S., Hoppenbrowers M.L.J.A., Gelders Y.G., and Reyntjens A.J.M. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind, placebo-controlled study versus lorazepam. Pharmacopsychiatry 18 (1985) 303-305
38. 2A receptors. Eur. J. Pharmacol. 334 (1997) 25-29
39. Charney D.S., and Heninger G.R. Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Arch. Gen. Psychiatry 43 (1986) 1059-1065
40. Chopin P., and Briley M. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol. Sci. 8 (1987) 383-388
41. 1B, and serotonin transporter expression across the anteroposterior axis of the rat dorsal and median raphe nuclei. J. Comp. Neurol. 498 (2006) 611-623
42. Cohen H. Anxiolytic effect and memory improvement in rats by antisense oligodeoxynucleotide to 5-hydroxytryptamine-2A precursor protein. Depress. Anxiety 22 (2005) 84-93
43. 2 binding site. J. Neurosci. 6 (1986) 3669-3675
44. 3 receptor agonists and antagonists for alteration of aversive behaviour in the mouse. Br. J. Pharmacol. 96 (1989) 325-332
45. 2 receptors. Psychopharmacology 93 (1987) 502-506
46. 1A ligands in the elevated X-maze and effects of dorsal raphe lesions. Psychopharmacology 106 (1992) 484-490
47. Davis M. The role of the amygdala in fear and anxiety. Annu. Rev. Neurosci. 15 (1992) 353-375
48. 2A receptors in the rat dorsal periaqueductal gray. Psychopharmacology 183 (2006) 422-428
49. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121 (1995) 1-26
50. Deakin J.F.W., and Graeff F.G. 5-HT and mechanisms of defence. J. Psychopharmacol. 5 (1991) 305-315
51. Delgado P.L., and Moreno F.A. Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. Br. J. Psychiatry Suppl. 35 (1998) 21-25
52. den Boer J.A., and Westenberg H.G.M. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102 (1990) 85-94
53. 2 receptors subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology 179 (2005) 418-429
54. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., Huang Y., Gautier C., and Mathis C. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 46 (1999) 1375-1387
55. Erzegovesi S., Martucci L., Henin M., and Bellodi L. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology 24 (2001) 31-36
56. Estes W.K., and Skinner F.B. Some quantitative properties of anxiety. J. Exp. Psychol. 29 (1941) 390-400
57. 1B receptors in knock-out mice lacking the 5-HT transporter. Eur. J. Neurosci. 12 (2000) 2299-2310
58. Fernandez M., Pissiota A., Frans O., von Knorring L., Fischer H., and Fredrikson M. Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study. Neurosci. Lett. 297 (2001) 101-104
59. Fowles D.C. Electrodermal hyporeactivity and antisocial behavior: does anxiety mediate the relationship?. J. Affect. Disord. 61 (2000) 177-189
60. Francken B.J.B., Jurzak M., Vanhauwe J.F.M., Luyten W.H.M.L., and Leysen J.E. The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK-293 cells. Eur. J. Pharmacol. 361 (1998) 299-309
61. Furmark T., Tillfors M., Garpenstrand H., Marteinsdottir I., Langstrom B., Oreland L., and Fredrikson M. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci. Lett. 362 (2004) 189-192
62. Furmark T., Tillfors M., Marteinsdottir I., Fischer H., Pissiota A., Langstrom B., and Fredrikson M. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch. Gen. Psychiatry 59 (2002) 425-433
63. Gallinat J., Strohle A., Lang U.E., Bajbouj M., Kalus P., Montag C., Seifert F., Wernicke C., Rommelspacher H., Rinneberg H., and Schubert F. Association of human hippocampal neurochemistry, serotonin transporter genetic variation, and anxiety. Neuroimage 26 (2005) 123-131
64. Gardner C.R. Recent developments in 5HT-related pharmacology of animal models of anxiety. Pharmacol. Biochem. Behav. 24 (1986) 1479-1485
65. Geller I., and Seifter J. The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1 (1960) 482-492
66. Germine M., Goddard A.W., Sholomskas D.E., Woods S.W., Charney D.S., and Heninger G.R. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res. 54 (1994) 115-133
67. 2C receptors but not by sympathomimetic effects. Neuropharmacology 33 (1994) 457-465
68. Gobbi G., Murphy D.L., Lesch K., and Blier P. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J. Pharmacol. Exp. Ther. 296 (2001) 987-995
69. Goddard A.W., Woods S.W., Sholomskas D.E., Goodman W.K., Charney D.S., and Heninger G.R. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 48 (1993) 119-133
70. Goldberg H.L., and Finnerty R.J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry 136 (1979) 1184-1187
71. Goodman W.K., McDougle C.J., Price L.H., Barr L.C., Hills O.F., Caplik J.F., Charney D.S., and Heninger G.R. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol. Psychiatry 38 (1995) 138-149
72. Gordon J.A., and Hen R. The serotonergic system and anxiety. Neuromolecular Med. 5 (2004) 27-40
73. Gottesman I.I., and Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160 (2003) 636-645
74. Graeff FG. Serotonin, the periaqueductal gray and panic. Neurosci. Biobehav. Rev. 28 (2004) 239-259
75. Graeff F.G., Netto C.F., and Zangrossi Jr. H. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23 (1998) 237-246
76. Graeff F.G., Parente A., Del-Ben C.M., and Guimarães F.S. Pharmacology of human experimental anxiety. Braz. J. Med. Biol. Res. 36 (2003) 421-432
77. Graeff F.G., and Schoenfeld R.I. Tryptaminergic mechanisms in punished and nonpunished behavior. J. Pharmacol. Exp. Ther. 173 (1970) 277-283
78. Graeff F.G., and Silveira Filho N.G. Behavioral inhibition induced by electrical stimulation of the median raphe nucleus of the rat. Physiol. Behav. 21 (1978) 477-484
79. Graeff F.G., Viana M.B., and Mora P. Dual role of 5-HT in defense and anxiety. Neurosci. Biobehav. Rev. 21 (1997) 791-799
80. Graeff F.G., Viana M.B., and Tomaz C. The elevated T maze, a new experimental model of anxiety and memory: effect of diazepam. Braz. J. Med. Biol. Res. 26 (1993) 67-70
81. 5B receptor was lost during mammalian evolution. Eur. J. Pharmacol. 418 (2001) 15-167
82. Gray J.A. The neuropsychology of anxiety (1982), Oxford University Press, New York, NY
83. Gray J.A., and McNaughton N. The neuropsychology of anxiety. 2nd edn (2000), Oxford University Press, New York, NY
84. Green A.R. Neuropharmacology of 5-hydroxytryptamine. Br. J. Pharmacol. 147 (2006) S145-S152
85. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65 (1995) 319-395
86. Griebel G., Cohen C., Perrault G., and Sanger D.J. Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiol. Behav. 67 (1999) 315-320
87. 2C receptors in the rat choroid plexus. Behav. Pharmacol. 5 (1994) 642-645
88. Griebel G., Rodgers R.J., Perrault G., and Sanger D.J. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol. Biochem. Behav. 57 (1997) 817-827
89. Gross C., Zhuang X., Stark K., Ramboz S., Oosting R., Kirby L., Santarelli L., Beck S., and Hen R. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416 (2002) 396-400
90. Guimarães F.S., Zuardi A.W., and Graeff F.G. Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J. Psychopharmacol. 1 (1987) 184-192
91. Handley S.L., McBlane J.W., Critchley M.A.E., and Njung'e K. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav. Brain Res. 58 (1993) 203-210
92. Handley S.L., and Mithani S. Effects of alpha-adrenoceptor agonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmiedeberg's Arch. Pharmacol. 327 (1984) 1-5
93. Hariri A.R., Drabant E.M., Munoz K.E., Kolachana B.S., Mattay V.S., Egan M.F., and Weinberger D.R. A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiatry 62 (2005) 146-152
94. Hariri A.R., and Holmes A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn. Sci. 10 (2006) 182-191
95. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., and Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 297 (2002) 400-403
96. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., and Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66 (1996) 2621-2624
97. 1A receptor mutant mice. Proc. Natl. Acad. Sci. USA 95 (1998) 15049-15054
98. Hensler J.G. Serotonergic modulation of the limbic system. Neurosci. Biobehav. Rev. 30 (2006) 203-214
99. Hesse S., Barthel H., Schwarz J., Sabri O., and Müller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci. Biobehav. Rev. 28 (2004) 547-563
100. Hetem L.A. Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder-a case report. J. Clin. Psychopharmacol. 16 (1996) 77-78
101. Hewlett W.A., Schmid S.P., and Salomon R.M. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J. Clin. Psychiatry 64 (2003) 1025-1030
102. 3 receptor antagonists. Psychopharmacology 104 (1991) 545-551
103. Hodges H., Green S., and Glenn B. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not in discrimination. Psychopharmacology 92 (1987) 491-504
104. Hoehn-Saric R., Schlund M.W., and Wong S.H. Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res. 131 (2004) 11-21
105. Holmes A., le Guisquet A.M., Vogel E., Millstein R.A., Leman S., and Belzung C. Early life genetic, epigenetic and environmental factors shaping emotionality in rodents. Neurosci. Biobehav. Rev. 29 (2005) 1335-1346
106. Holmes A., Lit Q., Murphy D.L., Gold E., and Crawley J.N. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav. 2 (2003) 365-380
107. 1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28 (2003) 2077-2088
108. Holmes A., Yang R.J., Murphy D.L., and Crawley J.N. Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27 (2002) 914-923
109. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71 (2002) 533-554
110. 3A modulates neural activation in the human amygdala. J. Neurosci. 25 (2005) 6460-6466
111. 1C) receptors on periaqueductal gray aversion. Eur. J. Pharmacol. 161 (1989) 219-221
112. Jenck F., Broekkamp C.L.E., and van Delft A.M.L. The effect of antidepressants on aversive PAG stimulation. Eur. J. Pharmacol. 177 (1990) 201-204
113. Jorge S.D., Pobbe R.L., De Paula V.S., Oliveira A.M., and Zangrossi Jr. H. Effects of sibutramine on anxiety-related behaviours in rats. Pharmacol. Res. 50 (2004) 517-522
114. Kahn R.J., McNair D.M., Lipman R.S., Covi L., Rickels K., Downing R., Fisher S., and Frankenthaler L.M. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II Efficacy in anxious outpatients. Arch. Gen. Psychiatry 43 (1986) 79-85
115. Kelleher R.T., and Morse W.H. Determinants of the specificity of behavioral effects of drugs. Ergeb. Physiol. 60 (1968) 1-56
116. Kia H.K., Brisorgueil M.J., Hamon M., Calas A., and Verge D. Ultrastructural localization of 5-hydroxytryptamine1A receptors in the rat brain. J. Neurosci. Res. 46 (1996) 697-708
117. Kia H.K., Miquel M.C., Brisorgueil M.J., Daval G., Riad M., El Mestikawy S., Hamon M., and Verge D. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J. Comp. Neurol. 365 (1996) 289-305
118. Kim D.K., Tolliver T.J., Huang S.J., Martin B.J., Andrews A.M., Wichems C., Holmes A., Lesch K.P., and Murphy D.L. Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology 49 (2005) 798-810
119. Kim H., Lim S.W., Kim S., Kim J.W., Chang Y.H., Carroll B.J., and Kim D.K. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. J. Am. Med. Assoc. 296 (2006) 1609-1618
120. Kiser R.S., German D.C., and Lebovitz R.M. Serotonergic reduction of dorsal central gray area stimulation-produced aversion. Pharmacol. Biochem. Behav. 9 (1978) 27-31
121. Kiser Jr. R.S., and Lebovitz R.M. Monoaminergic mechanisms in aversive brain stimulation. Physiol. Behav. 15 (1975) 47-53
122. Kiser R.S., Lebovitz R.M., and German D.C. Anatomic and pharmacologic differences between two types of aversive midbrain stimulation. Brain Res. 155 (1978) 331-342
123. Klein F.F., and Flink M. Psychiatric reaction patterns to imipramine. Am. J. Psychiatry 119 (1962) 432-438
124. Koe B.K., and Weissman A. p-Chlorophenylalanine: a specific depletor of brain serotonin. J. Pharmacol. Exp. Ther. 154 (1966) 499-516
125. Koks S., Beljajev S., Koovit I., Abramov U., Bourin M., and Vasar E. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology 153 (2001) 365-372
126. Koszycki D., Zacharko R.M., Le Melledo J.M., Young S.N., and Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol. Psychiatry 40 (1996) 648-655
127. Lanzenberger, R.R, Mitterhauser, M., Spindelegger, C., Wadsak, W., Klein, N., Mien, L.-K., Holik, A., Attarbaschi, T., Mossaheb, N., Sacher, J., Geiss-Granadia, T., Kletter, K., Kasper, S. and Tauscher, J. (2007) Reduced serotonin-1A receptor binding in social anxiety disorder. Biol. Psychiatry, 61: 1081-1089.
128. Lecrubier Y., Pucch A.J., Azeona A., Bailey P.E., and Lataste X. A randomized double-blind place-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 112 (1999) 129-133
129. LeDoux J.E. Emotional memory systems in the brain. Behav. Brain Res. 58 (1993) 69-79
130. Leonardo E.D., and Hen R. Genetics of affective and anxiety disorders. Annu. Rev. Psychol. 57 (2006) 117-137
131. Lesch K.P. Genetic alterations of the murine serotonergic gene pathway: the neurodevelopmental basis of anxiety. Handb. Exp. Pharmacol. 169 (2005) 71-112
132. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamim J., Müller C.R., Hamer D.H., and Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
133. Lesch K.P., Hoh A., Disselkamp-Tietze J., Wiesmann M., Osterheider M., and Schulte H.M. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch. Gen. Psychiatry 48 (1991) 540-547
134. 1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106 (1992) 111-117
135. Lesch K.P., Zeng Y., Reif A., and Gutknecht L. Anxiety-related traits in mice with modified genes of the serotonergic pathway. Eur. J. Pharmacol. 480 (2003) 185-204
136. Levi G., and Raiteri M. Carrier-mediated release of neurotransmitters. Trends Neurol. Sci. 16 (1993) 415-419
137. 1A) in 5-HT transporter knock-out mice: gender and brain region differences. J. Neurosci. 20 (2000) 7888-7895
138. 1A binding sites in 5-HT transporter knockout mice. J. Pharmacol. Exp. Ther. 291 (1999) 999-1007
139. 2C receptors in serotonin transporter knockout mice. J. Neurochem. 84 (2003) 1256-1265
140. Lowry C.A., Johnson P.L., Hay-Schmidt A., Mikkelsen J., and Shekhar A. Modulation of anxiety circuits by serotonergic systems. Stress 8 (2005) 233-246
141. Maier S.F., and Watkins L.R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci. Biobehav. Rev. 29 (2005) 829-841
142. 123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol. Psychiatry 44 (1998) 1090-1098
143. Mansari M.E., and Blier P. Mechanism of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Progress Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006) 362-373
144. Maron E., Kuikka J.T., Ulst K., Tiihonen J., Vasar V., and Shlik J. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur. Arch. Psychiatry Clin. Neurosci. 254 (2004) 392-396
145. Maron E., and Shlik J. Serotonin function in panic disorder: important, but why?. Neuropsychopharmacology 31 (2006) 1-11
146. Maron E., Toru I., Vasar V., and Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J. Psychopharmacol. 18 (2004) 194-199
147. 2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol. Biochem. Behav. 71 (2002) 615-625
148. 2 ligands on benzodiazepines co-administration: comparison of two animal models of anxiety (the tour-plate test and the elevated plus maze). Behav. Brain Res. 177 (2007) 214-226
149. Mathews T.A., Fedele D.A., Coppelli F.M., Avila A.M., Murphy D.L., and Andrews A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Meth. 140 (2004) 169-181
150. Mcblane J.W., and Handley S.L. Effects of two stressors on behavior in the elevated X-maze: preliminary investigation of their interaction with 8-OH-DPAT. Psychopharmacology 116 (1994) 173-182
151. McBride P.A., DeMeo M.D., Sweeney J.A., Halper J., Mann J.J., and Shear M.K. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. Biol. Psychiatry 31 (1992) 19-34
152. McNair D.M., Frankenthaler L.M., Czerlinsky T., White T.W., Sasson S., and Fisher S. Simulated public speaking as a model of clinical anxiety. Psychopharmacology 77 (1982) 7-10
153. McNaughton N., and Corr P.J. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci. Biobehav. Rev. 28 (2004) 285-305
154. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 53-244
155. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110 (2006) 135-370
156. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60 (2006) 441-460
157. Millenson J.R., and Leslie J. The conditioned emotional response (CER) as a baseline for the study of anti-anxiety drugs. Neuropharmacology 13 (1974) 1-9
158. 2-induced anxiety in patients with panic disorder and normal volunteers. Br. J. Psychiatry 176 (2000) 182-188
159. 2C receptors subtypes in the two types of fear generated by the elevated T-maze. Pharmacol. Biochem. Behav. 58 (1997) 1051-1057
160. Mortimore C., and Anderson I.M. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacology 149 (2000) 251-258
161. 1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam. Br. J. Pharmacol. 99 (1990) 343-349
162. 3 receptors in forebrain of serotonin transporter deficient mice. J. Neural Transm. 111 (2004) 27-35
163. 1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology 107 (1992) 135-139
164. Munjack D.J., Crocker B., Cable D., Brown R., Usigli R., Zulueta A., McManus M., McDowell D., Palmer R., and Leonard M. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Clin. Psychopharmacol. 9 (1989) 22-27
165. Murphy D.L., Zohar J., Benkelfat C., Pato M.T., Pigott T.A., and Insel T.R. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br. J. Psychiatry Suppl. 8 (1989) 15-24
166. Neumeister A., Bain E., Nugent A.C., Carson R.E., Bonne O., Luckenbaugh D.A., Eckelman W., Herscovitch P., Charney D.S., and Drevets W.C. Reduced serotonin type 1A receptor binding in panic disorder. J. Neurosci. 24 (2004) 589-591
167. Nogueira R.L., and Graeff F.G. Mediation of the antiaversive effect of isamoltane injected into the dorsal periaqueductal grey. Behav. Pharmacol. 2 (1991) 73-77
168. Nogueira R.L., and Graeff F.G. Role of 5-HT receptor subtypes in the modulation of aversion generated in the dorsal periaqueductal gray. Pharmacol. Biochem. Behav. 52 (1995) 1-6
169. Nutt D.J. The pharmacology of human anxiety. Pharmacol. Ther. 47 (1990) 233-266
170. Ogilvie A.D., Battersby S., Bubb V.J., Fink G., Harmar A.J., Goodwim G.M., and Smith C.A. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347 (1996) 731-733
171. Olivier B., Zethof T., Parttij T., van Boogaert M., van Oorschot R., Leahy C., Oosting R., Bouwknecht A., Veening J., van der Gugten J., and Groenink L. Stress-induced hyperthermia and anxiety: pharmacological validation. Eur. J. Pharmacol. 463 (2003) 117-132
172. Palkovits M., Brownstein M., and Saavedra J.M. Serotonin content of the brain stem nuclei in the rat. Brain Res. 80 (1974) 237-249
173. Parks C.L., Robinson P.S., Sibille E., Shenk T., and Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl. Acad. Sci. USA 95 (1998) 10734-10739
174. Pazos A., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346 (1985) 205-230
175. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in the elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14 (1985) 149-167
176. Peng W.H., Wu C.R., Chen C.S., Chen C.F., Leu Z.C., and Hsieh M.T. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors. Life Sci. 75 (2004) 2451-2462
177. 2 hyperreactivity and short-term treatment outcome. J. Clin. Psychopharmacol. 22 (2002) 300-308
178. Peroutka S.J. 5-hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci. 11 (1988) 496-500
179. Petersen, E.N. and Scheel-Krüger, J. (1984) Anticonflict effects of 5-HT antagonists by intraamygdaloid injection. Abstracts of the 14th CINP Congress, pp. 654.
180. Pezawas L., Meyer-Lindenberg A., Drabant E.M., Verchinski B.A., Munoz K.E., Kolachana B.S., Egan M.F., Mattay V.S., Hariri A.R., and Weinberger D.R. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat. Neurosci. 8 (2005) 828-834
181. Piñeyro G., and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51 (1999) 534-591
182. Pinheiro, S.N., Zangrossi, H. Jr., Del-Ben, C.M. and Graeff, F.G. (2007) Elevated mazes as animal models of anxiety: effects of serotonergic agents. An. Acad. Bras. Cienc., 79: 71-85.
183. 2A receptors in the rat dorsal periaqueductal gray mediate the antipanic-like effect induced by the stimulation of serotonergic neurons in the dorsal raphe nucleus. Psychopharmacology 183 (2005) 314-321
184. Poltronieri S.C., Zangrossi Jr. H., and Viana M.B. Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav. Brain Res. 147 (2003) 185-192
185. Prut L., and Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463 (2003) 3-33
186. 1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl. Med. Biol. 27 (2000) 509-513
187. Ramboz S., Oosting R., Amara D.A., Kung H.F., Blier P., Mendelsohn M., Mann J.J., Brunner D., and Hen R. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. USA 95 (1998) 14476-14481
188. Rapport M.M. Serum vasoconstrictor (serotonin). V. The presence of creatinine in the complex: a proposed structure of the vasoconstrictor principle. J. Biol. Chem. 180 (1949) 961-969
189. Reist C., Mazzanti C., Vu R., Tran D., and Goldman D. Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. Am. J. Med. Genet. 105 (2001) 363-368
190. Rickels K., Downing R., Scweizer E., and Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry 50 (1993) 884-895
191. 2A receptors in mice lacking the serotonin transporter. Neurosci. Lett. 262 (1999) 113-116
192. Robichaud R.C., and Sledge K.L. The effects of p-chlorophenylalanine on experimentally induced conflict in the rat. Life Sci. 8 (1969) 965-969
193. 3 antagonist, in benzodiazepine discontinuation. J. Clin. Psychopharmacol. 18 (1998) 121-131
194. Sanchez C. Stress-induced vocalization in adult animals. A valid model of anxiety?. Eur. J. Pharmacol. 463 (2003) 133-143
195. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., and Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
196. 1A receptor binding in human temporal lobe epilepsy. Neurology 62 (2004) 1343-1351
197. Schenberg L.C., and Graeff F.G. Role of the periaqueductal gray substance in the antianxiety action of benzodiazepines. Pharmacol. Biochem. Behav. 9 (1978) 287-295
198. Schoenfeld R.I. Lysergic acid diethylamide- and mescaline-induced attenuation of the effect of punishment in the rat. Science 192 (1976) 801-803
199. Schruers K., van Diest R., Overbeek T., and Griez E. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res. 113 (2002) 237-243
200. Schütz M.T.B., de Aguiar J.C., and Graeff F.G. Anti-aversive role of serotonin on the dorsal periaqueductal grey matter. Psychopharmacology 85 (1985) 340-345
201. Sena L.M., Bueno C., Pobbe R.L., Andrade T.G., Zangrossi H., and Viana M.B. The dorsal raphe nucleus exerts opposed control on generalized anxiety and panic-related defensive responses in rats. Behav. Brain Res. 142 (2003) 125-133
202. Setem J., Pinheiro A.P., Motta V.A., Morato S., and Cruz A.P. Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacol. Biochem. Behav. 62 (1999) 515-521
203. Shlik J., Maron E., Tru I., Aluoja A., and Vasar V. Citalopram challenge in social anxiety disorder. Int. J. Neuropsychopharmacol. 7 (2004) 177-182
204. Sibille E., Pavlides C., Benke D., and Toth M. Genetic inactivation of the serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci. 20 (2000) 2758-2765
205. Silva R.C., and Brandão M.L. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol. Biochem. Behav. 65 (2000) 209-216
206. Smits K.M., Smits L.J., Schouten J.S., Stelma F.F., Nelemans P., and Prins M.H. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry 9 (2004) 433-441
207. Solyom L. Controlling panic attacks with fenfluramine. Am. J. Psychiatry 151 (1994) 621-622
208. Southwick S.M., Krystal J.H., Bremner J.D., Morgan III C.A., Nicolaou A.L., Nagy L.M., Johnson D.R., Heninger G.R., and Charney D.S. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 54 (1997) 749-758
209. Southwick S.M., Paige S., Morgan III C.A., Bremner J.D., Krystal J.H., and Charney D.S. Neurotransmitter alterations in PTSD: catecholamines and serotonin. Semin. Clin. Neuropsychiatry 4 (1999) 242-248
210. 1A receptor binding and anxiety: a[(11)C]WAY-100635 PET investigation in healthy volunteers. Am. J. Psychiatry 158 (2001) 1326-1328
211. Teixeira R.C., Zangrossi Jr. H., and Graeff F.G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol. Biochem. Behav. 65 (2000) 571-576
212. Tye N.C., Everitt B.J., and Iversen S.D. 5-Hydroxytryptamine and punishment. Nature 268 (1977) 741-742
213. Van der Linden G., van Heerden B., Warwick J., Wessels C., van Kradenburg J., Zungu-Dirwayi N., and Stein D.J. Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2000) 419-438
214. van Megen H.J., Westenberg H.G., den Boer J.A., Slaap B., and Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 129 (1997) 357-364
215. van Vliet I.M., Slaap B.R., Westenberg H.G., and Den Boer J.A. Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur. Neuropsychopharmacol. 6 (1996) 103-110
216. 1A receptor agonist flesinoxan in panic disorder. Psychopharmacology 127 (1996) 174-180
217. Viana M.B., Graeff F.G., and Löschmann P.-A. Kainate microinjection into the dorsal raphe nucleus induces 5-HT release in the amygdala and periaqueductal gray. Pharmacol. Biochem. Behav. 58 (1997) 167-172
218. 2A receptor signiling modulates anxiety-like behaviors in mice. Science 313 (2006) 536-540
219. Wise C.D., Berger B.D., and Stein L. Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 177 (1972) 180-183
220. Wrase J., Reimold M., Puls I., Kienast T., and Heinz A. Serotonergic dysfunction: brain imaging and behavioral correlates. Cogn. Affect. Behav. Neurosci. 6 (2006) 53-61
221. 1A receptor binding in amygdala of schizophrenia. Biol. Psychiatry 55 (2004) 439-444
222. Yu Y.W., Tsai S.J., Chen T.J., Lin C.H., and Hong C.J. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry 7 (2002) 1115-1119
223. Zangrossi Jr. H., Viana M.B., and Graeff F.G. Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2(di-n-propylamino)tetralin in the elevated T-maze. Eur. J. Pharmacol. 369 (1999) 267-270
224. Zanoveli J.M., Netto C.F., Guimarães F.S., and Zangrossi Jr. H. Systemic and intra-dorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8 s) induce a panic-like response in rats submitted to the elevated T-maze. Peptides 25 (2004) 1935-1941
225. Zanoveli J.M., Nogueira R.L., and Zangrossi Jr. H. Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviors in the elevated T-maze. Eur. J. Pharmacol. 473 (2003) 153-161
226. 2A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav. Pharmacol. 16 (2005) 543-552